PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11096240-0	2000	Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer.	Dextrans	36-43	epidermal growth factor	Homo sapiens	31-34	
11096240-3	2000	The aim of this study was to determine if intravesically administered EGF-dextran conjungate selectively accumulated in the tumor tissue and to correlate the uptake to tumor characteristics.	Dextrans	74-81	epidermal growth factor	Homo sapiens	70-73	
11096240-6	2000	RESULTS: Five patients received EGF-dextran-(99m)Tc, three received dextran-(99m)Tc and one received only (99m)Tc.	Dextrans	36-43	epidermal growth factor	Homo sapiens	32-35	
11096240-9	2000	CONCLUSION: The results are encouraging and further studies are warranted to investigate if EGF-dextran could be effective as intravesical therapy, either conjugated with cystostatic drugs or labeled with suitable radionuclides.	Dextrans	96-103	epidermal growth factor	Homo sapiens	92-95